EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Drug Repurposing in Sickle Cell Disease: Evaluating Imatinib as a Therapeutic Candidate

Bijan Keikhaei iD, Daryush Purrahman iD, Najmeh Nameh Goshay Fard iD, Elham Abedi iD, Farnoush Farokhian iD, Reyhane Khademi iD

Pediatric Blood & Cancer · 2026-10 · 73 (10)

DOI: 10.1002/1545-5017.70606 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 04.08.2026. Verfasst von Bijan Keikhaei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Imatinib Mesylate, Drug Repositioning, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is an inherited hemolytic hemoglobinopathy characterized by chronic hemolysis, vaso‐occlusive pain crises, and progressive organ damage. Hydroxyurea, often combined with analgesics, remains a mainstay therapy, but may provide insufficient relief during active disease episodes. Drug repurposing offers a practical alternative where de novo drug development is limited, providing faster and more cost‐effective therapeutic options. Imatinib (Gleevec), a tyrosine kinase inhibitor primarily used for chronic myeloid leukemia, has gained attention as a potential repurposed therapy for SCD. This narrative review provides a theoretical framework for evaluating imatinib's potential applications in mitigating key pathophysiological processes in SCD. Examination of the molecular pathways shared between imatinib's targets and the pathogenesis of SCD has yielded mixed findings: some studies suggest imatinib may reduce hemolysis and alleviate pain crises, while others have not supported such benefits. Direct investigations of imatinib in the context of SCD are limited, yet available evidence has reported potentially valuable outcomes, including decreased hospitalization rates, shorter hospital durations, and reduced organ damage. Current evidence remains insufficient for definitive conclusions, underscoring the need for well‐designed clinical and translational studies to clarify the feasibility of incorporating imatinib into SCD management. Summary Imatinib has actions on signaling pathways with potential clinical relevance to sickle cell disease, such as reduction of inflammation, vaso‐occlusive crises, and opioid tolerance. Reports of use in patients with sickle cell disease suggest potential for reducing the frequency of vaso‐occlusive crises.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellImatinib MesylateDrug RepositioningProtein Kinase InhibitorsHumansVaso-Occlusive Crises

Stichwörter der Autor:innen

drug repositioninghemolysisimatinibinflammationsickle cell diseasevaso‐occlusive crisis

Substanzen

Imatinib MesylateProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Bijan Keikhaei, Daryush Purrahman, Najmeh Nameh Goshay Fard, Elham Abedi, Farnoush Farokhian, Reyhane Khademi

Zitieren

APA

Keikhaei, B., Purrahman, D., Nameh Goshay Fard, N., Abedi, E., Farokhian, F., & Khademi, R. (2026). Drug Repurposing in Sickle Cell Disease: Evaluating Imatinib as a Therapeutic Candidate. Pediatric Blood & Cancer, 73(10). https://doi.org/10.1002/1545-5017.70606

Vancouver

Keikhaei B, Purrahman D, Nameh Goshay Fard N, Abedi E, Farokhian F, Khademi R. Drug Repurposing in Sickle Cell Disease: Evaluating Imatinib as a Therapeutic Candidate. Pediatric Blood & Cancer. 2026;73(10). doi:10.1002/1545-5017.70606

BibTeX
@article{Keikhaei2026,
  author = {Keikhaei, Bijan and Purrahman, Daryush and Nameh Goshay Fard, Najmeh and Abedi, Elham and Farokhian, Farnoush and Khademi, Reyhane},
  title = {Drug Repurposing in Sickle Cell Disease: Evaluating Imatinib as a Therapeutic Candidate},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {10},
  doi = {10.1002/1545-5017.70606}
}
Kostenlos starten →